Breednet: First Stakes Winner for Divine Prophet

From Breednet: Fifteen two-year-old fillies charged down the Flemington straight in the Group III Darley Ottawa Stakes (1000m) on Oaks Day and it was the unraced division that dominated the finish.

Looking every inch a true professional, the Richard and Chantelle Jolly-trained See You in Heaven went straight as an arrow down the centre of the track to ring up the first stakes-winner for Aquis Farm’s Caulfield Guineas hero Divine Prophet (Choisir).

Read More

Breednet: The Mission Off The Mark

The Mission

From Breednet: Aquis Farm’s The Mission became the third first crop stallion to put a winner on the board when the Les Ross-trained Mishani Warfare scored a richly deserved win in the Moet & Chandon Hcp (1200m) at Eagle Farm on Saturday.

A close-up second on debut in the $75,000 Pat O’Shea Stakes at Toowoomba on September 5, Mishani Warfare clocked in third in the $105,000 Widden – Basil Nolan Jnr Plate (1000m) at Eagle Farm on October 9.

Read More

Breednet: Breednet Follows the Sydney 2YO Trials Heat 1 – 5

Spieth (NZ)

From Breednet: HEAT FIVE 855m – 50.22 seconds- Aquis Farm’s Spieth posted his second winner at this set of trials when the Kacy Fodgen trained colt Victory Moments  hit the line hard to beat $1,150,000 I Am Invincible colt Zambezi River by a length and three-quarters.

Victory Moments had trial experience having beaten his stablemate Wild Botanica in a heat at the Gold Coast on September 6.

Read More

Breednet: Mission Possible – Two More Trial Winners for The Mission

The Mission

From Breednet: Excitement is building at Camp Aquis following the 2YO heats at Doomben on Tuesday morning – the third lot of juvenile trials in Queensland this season.

Aquis Farm’s first season sire, Spieth, got off to a literal flyer at the Gold Coast last week when three of his youngsters ran 1st, 2nd and 4th in the opening heat, while his ‘freshman’ mate, The Mission, repeated the dose at Deagon the following day: likewise notching up a heat winner, alongside other promising triallists.

Read More